Prostate-Specific Antigen (PSA) Levels and Prostate Cancer Risk
Introduction to PSA and Cancer Risk
- The American Cancer Society recommends that prostate cancer risk exists on a continuum at all PSA levels, with no absolute cutoff below which prostate cancer is absent 1
Cancer Risk by PSA Level
- For men with PSA levels between 0-0.5 ng/mL, the cancer risk is 6.6% (12.5% high-grade) 2
- For men with PSA levels between 0.6-1.0 ng/mL, the cancer risk is 10.1% (10.0% high-grade) 2
- For men with PSA levels between 1.1-2.0 ng/mL, the cancer risk is 17.0% (11.8% high-grade) 2
- For men with PSA levels between 2.1-3.0 ng/mL, the cancer risk is 23.9% 2
- For men with PSA levels between 3.1-4.0 ng/mL, the cancer risk is 26.9% 2
Age-Specific Reference Ranges
- For men aged 40-49, the PSA reference range is 0-2.0 ng/mL for Asian-Americans and African-Americans, and 0-2.5 ng/mL for Whites 2
- For men aged 50-59, the PSA reference range is 0-3.0 ng/mL for Asian-Americans, 0-4.0 ng/mL for African-Americans, and 0-3.5 ng/mL for Whites 2
- For men aged 60-69, the PSA reference range is 0-4.0 ng/mL for Asian-Americans, 0-4.5 ng/mL for African-Americans, and 0-4.5 ng/mL for Whites 2
- For men aged 70-79, the PSA reference range is 0-5.0 ng/mL for Asian-Americans, 0-5.5 ng/mL for African-Americans, and 0-6.5 ng/mL for Whites 2
Median PSA Values in Cancer-Free Men
- The median PSA in men without cancer is 0.7 ng/mL for men in their 40s, 0.9 ng/mL for men in their 50s, 1.2 ng/mL for men in their 60s, and 1.5 ng/mL for men in their 70s 2
PSA Velocity Considerations
- A rise of ≥0.75 ng/mL per year is concerning for men with PSA ≤4.0 ng/mL 2
- Age-adjusted velocity thresholds are 0.25 ng/mL/year for ages 40-59, 0.5 ng/mL/year for ages 60-69, and 0.75 ng/mL/year for ages 70+ 2
- A PSA velocity >2.0 ng/mL/year in the year before diagnosis carries approximately 10-fold greater risk of prostate cancer death after treatment 3
Post-Treatment Context
- After radical prostatectomy, PSA should be undetectable (<0.1 ng/mL) within 8 weeks, and biochemical recurrence is defined as PSA ≥0.4 ng/mL at minimum 1 month post-surgery, confirmed on subsequent testing 4
- After radiation therapy, biochemical failure requires three consecutive PSA rises starting at least 2 years after radiation, with failure dated at the midpoint between nadir and first confirmed rise 4